PMID- 33100319 OWN - NLM STAT- MEDLINE DCOM- 20210707 LR - 20221207 IS - 1643-3750 (Electronic) IS - 1234-1010 (Print) IS - 1234-1010 (Linking) VI - 26 DP - 2020 Oct 26 TI - A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer. PG - e927654 LID - 10.12659/MSM.927654 [doi] AB - BACKGROUND Pancreatic cancer (PC) is a common digestive system tumor. For patients with advanced pancreatic cancer (APC), chemotherapy is still the predominant treatment. However, no large-scale clinical studies have been done of it as first-line therapy for APC. The goal of the present study was to assess real-world outcomes with chemotherapy in that setting. MATERIAL AND METHODS We retrospectively analyzed data from 322 patients with APC who were treated with chemotherapy at 4 hospitals in different cities in China. The first-line regimens used were AS (nab-paclitaxel and S-1), AG (nab-paclitaxel and gemcitabine), and FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin). RESULTS Of the patients, 232 received AS, 79 received AG, and 11 received FOLFIRINOX. The median number of chemotherapy cycles was 5. The median overall survival (mOS) was 9 months and the median progression-free survival (mPFS) was 5 months. The AS, AG, and FOLFIRINOX regimens were associated with mOS rates of 9 months, 9 months, and 10 months, respectively. The mPFS rates for the AS, AG, and FOLFIRINOX regimens were 5, 4, and 5 months, respectively. The differences between the PFS rates for the regimens were statistically significant. The overall response rate (ORR) and overall disease control rate (DCR) for chemotherapy were 38% and 81.8%, respectively. The ORRs for the AS, AG, and FOLFIRINOX regimens were 46.9%, 18.7%, and 0%, respectively. The DCRs for the AS, AG and FOLFIRINOX regimens were 87.2%, 69.3%, and 63.6%, respectively. The differences between the ORRs and DCRs for the regimens were statistically significant. The incidences of grade 3/4 adverse events (AEs) associated with the AS, AG, and FOLFIRINOX regimens were 29.9%, 25%, and 36.4%, respectively. CONCLUSIONS The AS regimen was associated with a higher ORR and DCR than the other 2 regimens, with a lower rate of AEs. FAU - Cui, Hanzhi AU - Cui H AD - Medical School of Chinese People's Liberation Army (PLA), Beijing, China (mainland). AD - Department of Oncology, The Eighth Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland). FAU - Guan, Jingzhi AU - Guan J AD - Department of Oncology, The Eighth Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland). FAU - Deng, Guochao AU - Deng G AD - Department of Oncology, The Eighth Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland). FAU - Yuan, Jiajia AU - Yuan J AD - Department of Oncology, Beijing Cancer Hospital, Beijing, China (mainland). FAU - Lou, Changjie AU - Lou C AD - Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China (mainland). FAU - Zhang, Wen AU - Zhang W AD - Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (mainland). FAU - Zhou, Aiping AU - Zhou A AD - Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (mainland). FAU - Zhang, Yanqiao AU - Zhang Y AD - Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China (mainland). FAU - Zhou, Jun AU - Zhou J AD - Department of Oncology, Beijing Cancer Hospital, Beijing, China (mainland). FAU - Dai, Guanghai AU - Dai G AD - Department of Oncology, The First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland). LA - eng PT - Clinical Trial PT - Journal Article PT - Multicenter Study DEP - 20201026 PL - United States TA - Med Sci Monit JT - Medical science monitor : international medical journal of experimental and clinical research JID - 9609063 RN - 0 (130-nm albumin-bound paclitaxel) RN - 0 (Albumins) RN - 0 (Antineoplastic Agents) RN - 0 (Drug Combinations) RN - 0 (folfirinox) RN - 04ZR38536J (Oxaliplatin) RN - 0W860991D6 (Deoxycytidine) RN - 150863-82-4 (S 1 (combination)) RN - 1548R74NSZ (Tegafur) RN - 5VT6420TIG (Oxonic Acid) RN - 7673326042 (Irinotecan) RN - P88XT4IS4D (Paclitaxel) RN - Q573I9DVLP (Leucovorin) RN - U3P01618RT (Fluorouracil) RN - 0 (Gemcitabine) SB - IM MH - Adult MH - Aged MH - *Albumins/adverse effects/therapeutic use MH - *Antineoplastic Agents/adverse effects/therapeutic use MH - *Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use MH - China MH - Deoxycytidine/adverse effects/*analogs & derivatives/therapeutic use MH - Drug Combinations MH - Female MH - Fluorouracil/adverse effects/therapeutic use MH - Humans MH - Irinotecan/adverse effects/therapeutic use MH - Leucovorin/adverse effects/therapeutic use MH - Male MH - Middle Aged MH - Oxaliplatin/adverse effects/therapeutic use MH - *Oxonic Acid/adverse effects/therapeutic use MH - *Paclitaxel/adverse effects/therapeutic use MH - Pancreatic Neoplasms/*drug therapy MH - Progression-Free Survival MH - Retrospective Studies MH - *Tegafur/adverse effects/therapeutic use MH - Gemcitabine PMC - PMC7597583 EDAT- 2020/10/27 06:00 MHDA- 2021/07/08 06:00 PMCR- 2020/10/26 CRDT- 2020/10/26 05:18 PHST- 2020/10/26 05:18 [entrez] PHST- 2020/10/27 06:00 [pubmed] PHST- 2021/07/08 06:00 [medline] PHST- 2020/10/26 00:00 [pmc-release] AID - 927654 [pii] AID - 10.12659/MSM.927654 [doi] PST - epublish SO - Med Sci Monit. 2020 Oct 26;26:e927654. doi: 10.12659/MSM.927654.